PMC10036805_01
Diagram of patient's treatment history and clinical course. (A) Timeline of treatment; (B) Imaging changes before and after treatment. PR: partial response; SD: stable disease; PFS: progression-free survival.
fonc-13-1091669-g001.jpg
PMC10036805_01_fonc-13-1091669-g001.jpg
f1
Genetic testing suggested KRAS E2p.G13D mutation ( Figure 1A ). Patients are not tolerated due to adverse reactions and are reviewed regularly ( Figure 1A ). Patients are not tolerated due to adverse reactions and are reviewed regularly (  Figure 1A  ). The patient started 1st-line treatment with mFOLFOX6+bevacizumab, lasting for seven cycles, and the disease was stable which achieved stable disease (SD) of the lung lesion ( Figure 1A ). The patient started 2nd-line treatment with FOLFIRI+Bevacizumab, lasting for eight cycles, and the disease was stable which yielded a partial response partial response (PR) of the lung lesion ( Figure 1A ). 2nd-line maintenance therapy was given with irinotecan and bevacizumab, lasting for two cycles and until November 2020 with a PFS of 7 months. The patient received 3rd-line treatment achieved maintain partial response (PR)( Figure 1B ).